OC-01 (varenicline 0.6mg/ml) nasal spray
Sponsors
Brandon Baartman, Vance Thompson Vision ND, Center for Ophthalmic and Vision Research, LLC
Conditions
Dry EyeDry Eye Disease
Phase 3
Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)
NCT05045508
Start: 2021-08-30End: 2023-01-30Target: 60Updated: 2021-09-22
Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)
CompletedNCT05082974
Start: 2021-10-20End: 2022-08-03Updated: 2023-06-12